Gemcitabine and Lenvatinib drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gemcitabine (gemcitabine) and Lenvatinib (lenvatinib). Common drug interactions include drug ineffective among females and thrombocytopenia among males.

The phase IV clinical study analyzes what interactions people have when they take Gemcitabine and Lenvatinib. It is created by eHealthMe based on reports of 46 people who take the same drugs from the FDA, and is updated regularly.

What is Gemcitabine?

Gemcitabine has active ingredients of gemcitabine. eHealthMe is studying from 31,337 Gemcitabine users. Check the latest studies of Gemcitabine.

What is Lenvatinib?

Lenvatinib has active ingredients of lenvatinib. eHealthMe is studying from 3,587 Lenvatinib users. Check the latest studies of Lenvatinib.

On Jul, 11, 2026

46 people who take Gemcitabine and Lenvatinib together, and have interactions are studied.

Gemcitabine and Lenvatinib drug interactions.

What are the common drug interactions of Gemcitabine and Lenvatinib, by gender? *:

female:

Drug ineffective
Disease progression
Myelosuppression (a decrease in the production of blood cells)
Nausea (feeling of having an urge to vomit)
Neoplasm progression (growth of tumour)

male:

Thrombocytopenia (decrease of platelets in blood)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Haematotoxicity (toxins that destroy red blood cells)
Peripheral sensory neuropathy (damage to one or more of your peripheral nerves)
Pneumonia
Superior vena cava syndrome (obstruction of blood flow through the superior vena cava)
Thyroglobulin increased
Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins)
Decreased appetite
Diarrhoea

What are the common drug interactions of Gemcitabine and Lenvatinib, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Thrombocytopenia (decrease of platelets in blood)
Death
Malignant neoplasm progression (cancer tumour came back)
Neoplasm progression (growth of tumour)
Drug ineffective
Hypoxia (low oxygen in tissues)
Myeloid leukaemia (a type of cancer in which the bone marrow makes abnormal myeloblasts)
Pulmonary embolism (blockage of the main artery of the lung)

30-39:

Disease progression
Drug ineffective

40-49:

Disease progression
Drug ineffective
Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins)
Death
Fatigue (feeling of tiredness)
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Decreased appetite
Diarrhoea
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
Leiomyosarcoma metastatic (a very rare soft tissue sarcoma (cancer) that grows in muscle tissue spreading to other parts)

50-59:

Mixed hepatocellular cholangiocarcinoma (a rare form of primary liver cancer)
Asthenia (weakness)
Decreased appetite
Diarrhoea
Drug ineffective
Fatigue (feeling of tiredness)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Disease progression
Drug resistance (reduction in effectiveness of a drug)
Anaemia (lack of blood)

60+:

Disease progression
Drug ineffective
Myelosuppression (a decrease in the production of blood cells)

What are the existing conditions these people have? *

Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins): 12 people, 26.09%
Mixed Hepatocellular Cholangiocarcinoma (a rare form of primary liver cancer): 11 people, 23.91%
Non-Renal Cell Carcinoma Of Kidney (cancer of kidney without involvement of renal cell): 6 people, 13.04%
Metastases To Lung (cancer spreads to lung): 5 people, 10.87%
Metastases To Abdominal Cavity (cancer spreads to abdominal cavity): 5 people, 10.87%
Pain: 3 people, 6.52%
Osteosarcoma Recurrent (reoccurrence of a cancerous (malignant) bone tumour): 3 people, 6.52%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 6.52%
Hepatocellular Carcinoma (liver cancer): 3 people, 6.52%
Constipation: 3 people, 6.52%

* Approximation only. Some reports may have incomplete information.

Do you take Gemcitabine and Lenvatinib?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously